What types of peptides does Thinheal supply?

Thinheal supplies generic peptide APIs, therapeutic peptides, GLP-1 analogues such as Semaglutide (CAS 910463-68-2), GLP-2 analogues, other gastrointestinal peptides, other therapeutic peptide APIs and cosmetic peptides for skin-care formulations.

Does Thinheal offer custom peptide development and CDMO services?

Yes. Thinheal provides project-based contract research and development, contract manufacturing and sales support, covering custom peptide development, process optimization, scale-up and commercial API supply through to formulation development.

What is Thinheal's production capacity?

Thinheal operates an R&D center and a production base in Hangzhou, China. Total production capacity for chemically synthesized peptides has reached the multi-ton level.

What documentation can buyers expect?

Each shipment is accompanied by batch analytical data such as a Certificate of Analysis. Additional documents required for supplier qualification or regulatory filings can be scoped with the sales and technical team for each project.

How do international buyers contact the right sales team?

Thinheal runs regional sales desks for USA & Europe, Russia & CIS & Europe, Asia, and the Middle East & East Asia. Buyers can also email info@thinheal.com or call +86 0571-86758863.

Custom Tesamorelin CAS：218949-48-5 Manufacturer, Manufacturers

1 / 1

Custom Tesamorelin CAS：218949-48-5 Manufacturer, Manufacturers

Tesamorelin is a synthetic growth hormone-releasing hormone analog. Its core function is to stimulate the pituitary gland to secrete growth hormone, thereby increasing the level of insulin-like growth factor-1. Unlike direct growth hormone administration, Tesamorelin works through a physiological regulatory mechanism, and is considered to have better targeting and a lower risk of side effects. Its most notable feature is its ability to selectively reduce visceral fat, rather than achieving systemic fat reduction or muscle gain. This makes it uniquely valuable in treating metabolic disorders associated with visceral fat accumulation.

Send Inquiry

Product Description

Therapeutic Areas

Tesamorelin's primary approved and investigated therapeutic areas focus on metabolic complications associated with HIV infection, and it is expanding into a wider range of metabolic diseases.

Approved Indication

HIV-associated Lipodystrophy with Excess Abdominal Fat

This is the only indication for Tesamorelin approved in multiple countries worldwide (including the United States, Canada, and the European Union). It is used to treat visceral fat hypertrophy in HIV-infected individuals undergoing antiretroviral therapy. It effectively reduces abdominal visceral fat, improves body shape, and may provide related metabolic benefits.

Key Research Area

Nonalcoholic Fatty Liver Disease / Nonalcoholic Steatohepatitis (NAFLD/NASH)

This is currently the most active area in the clinical development of Tesamorelin. Because NAFLD/NASH is closely associated with visceral fat accumulation and impaired growth hormone axis function, Tesamorelin has shown the potential to significantly reduce liver fat content and improve liver inflammation and fibrosis in multiple clinical trials, and is considered a highly promising therapeutic candidate.

Key Research Area

Obesity and Metabolic Syndrome

This study investigates the effects of reducing visceral fat and improving blood glucose and lipid profiles in a general obese population without HIV infection, especially those with visceral obesity and insulin resistance.

Key Research Area

Growth Hormone Deficiency

As a GHRH analog, it has also been studied for replacement therapy in adults with growth hormone deficiency.

Key Research Area

Cognitive Function

Based on the effects of the growth hormone/IGF-1 axis on brain function, preliminary studies have explored its effect on improving mild cognitive impairment, but it is still in the early stages.

Outlook & Development

Tesamorelin's prospects and development mainly revolve around its transformation from a "drug repurposing" approach, moving from a specialty drug for treating HIV-related complications to a potential blockbuster drug for treating a wide range of metabolic diseases, especially NASH.

Huge Market Potential

NASH/NAFLD affects billions of people worldwide, and currently there are very few approved effective drugs. If Tesamorelin can continue to demonstrate its efficacy and safety in large-scale phase III clinical trials, it is expected to enter a huge market.

Advantages of Mechanism of Action

Its mechanism of action, which regulates growth hormone and selectively reduces visceral fat through physiological pathways, is different from the current mainstream targets of NASH (such as FXR agonists and GLP-1 receptor agonists). It may provide patients with a new and differentiated treatment option, or be used for combination therapy.

Clinical Progress

Clinical Development Progress

• The completed Phase II clinical trial in the NASH field yielded positive results, significantly reducing liver fat and inflammatory markers.

• Larger-scale Phase III clinical trials are currently underway or planned, which is crucial for its ability to obtain approval for new indications.

Risk Analysis

Challenges and Uncertainties

High requirements for clinical endpoints: The approval of NASH drugs requires meeting strict endpoints, such as improving liver fibrosis without aggravating NASH, which places high demands on the design of the Phase III trial of Tesamorelin.

Intense Competition: Competition in the NASH/obesity field is fierce, especially with the significant effects of GLP-1 drugs (such as semaglutide and tirzepatide) on weight loss and metabolism improvement. Tesamorelin needs to find a clear market position in terms of efficacy, safety, or advantages for specific patient groups.

Long-term safety: Although the safety data for long-term use in HIV patients are good, long-term safety in a broader population (such as NASH patients) still needs to be closely monitored in phase III trials.

Strategic Focus

Future Direction

Successful transformation: Its future development is highly dependent on the success of clinical trials for the NASH indication.

Combination therapy: In the future, we may explore the combination of this therapy with other drugs with different mechanisms of action, such as GLP-1 receptor agonists and FXR agonists, in order to achieve synergistic effects.

Patient segmentation: It may enable precision treatment for subgroups of NASH/obese patients with relatively low growth hormone axis function or specific metabolic characteristics (such as significant visceral obesity).

Conclusion

In summary, Tesamorelin is at a critical turning point in its development. It has evolved from a successful specialty drug into a potentially important treatment for common metabolic diseases such as NASH. Its performance in late-stage clinical trials for NASH will directly determine its future market value and the breadth of its clinical applications.

Frequently Asked Questions (FAQ)

Q: What is Tesamorelin and how does it work?

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog. It works by stimulating the pituitary gland to release growth hormone, which increases insulin-like growth factor-1 (IGF-1) levels, selectively targeting and reducing visceral fat through physiological pathways.

Q: What is the primary approved indication for Tesamorelin?

Tesamorelin is approved in multiple regions (including the US, Canada, and EU) specifically for treating HIV-associated lipodystrophy with excess abdominal fat in individuals receiving antiretroviral therapy.

Q: How does Tesamorelin differ from direct growth hormone administration?

Unlike direct growth hormone administration, Tesamorelin operates via a natural physiological regulatory mechanism. This provides better therapeutic targeting, a lower risk of side effects, and selective reduction of visceral fat rather than systemic body fat loss.

Q: Why is Tesamorelin being researched for NAFLD and NASH treatment?

Because NAFLD and NASH are closely linked to visceral fat buildup and impaired growth hormone regulation, clinical trials have shown that Tesamorelin can effectively lower liver fat content while improving inflammation and liver fibrosis.

Q: What are the key challenges facing Tesamorelin in future clinical developments?

Key hurdles include meeting strict endpoints in Phase III trials for NASH approval, standing out against popular GLP-1 medications (like semaglutide), and validating long-term safety profiles in non-HIV patient groups.

Q: Can Tesamorelin be combined with other treatments?

Yes, future research points toward combination therapies with other agents—such as GLP-1 receptor agonists and FXR agonists—to create synergistic therapeutic benefits for complex metabolic conditions.